Building on a prior MJFF-funded collaboration targeting LRRK2, Montara's BrainOnly™ platform now targets the mTOR pathway — exploring a class of drugs with longstanding scientific interest but a ...
The NUZ-001 arm of the HEALEY ALS trial is expanding enrollment to 240 participants. NUZ-001 is an experimental ALS therapy ...
TOR', a protein in our body, becomes excessively activated in cancer cells, promoting cell growth and metastasis. Korean researchers have discovered for the first time in the world that '13-HODE'—a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results